Delta-He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD-1/PD-L1 Inhibitors.

Cancer Med · 2025 · PMC11971532 · PMID 40186416

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The low delta‐He group experienced a slightly higher incidence of AEs (26.0%) compared to the high delta‐He group (20.7%), although this difference did not reach statistical significance. 3.4.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.